Revvity has unveiled Signals for Startups, a new initiative created to help emerging biotechnology companies establish robust digital research environments from the earliest stages of development.
Through its Signals Software business, the company is expanding access to enterprise-level informatics tools that are typically adopted much later in a biotech company’s growth cycle.
The program is designed to give startups the technology and implementation support needed to build scalable scientific workflows while reducing operational complexity as they advance their research.
Enterprise Software Combined With Tailored Implementation Support
Signals for Startups brings together access to Revvity’s enterprise-grade Signals software with guided onboarding and preconfigured workflows designed specifically for smaller biotechnology organizations.
The offering is intended to help research teams deploy digital infrastructure more quickly, improve scientific efficiency, and generate value sooner.
By providing startup-specific best practices alongside the software, the program seeks to eliminate many of the barriers that smaller companies often encounter when implementing laboratory informatics systems.
Scalable Platform Built for Long-Term Growth
The new platform includes ready-to-use configurations for both large- and small-molecule research, allowing organizations to standardize scientific data, improve collaboration, and streamline research activities from the outset.
The program also provides bundled software licenses suited to early-stage biotech companies while creating a clear upgrade path as organizations expand through seed funding, venture capital investment, and later stages of commercialization.
This scalable approach enables companies to continue using the same digital ecosystem as their research operations grow.
Commercial Availability Planned Across Multiple Regions
Revvity expects Signals for Startups to become available in the United States as well as across Europe, the Middle East, and Africa beginning in late July 2026.
The regional rollout reflects the company’s effort to support biotechnology innovation across major global life sciences markets.
Revvity Continues Expanding Its Health Science Technology Portfolio
Headquartered in Waltham, Massachusetts, Revvity develops health science technologies, software, and services that support the full continuum of scientific research—from discovery and development to diagnostics and treatment.
Its expertise spans translational multi-omics, biomarker discovery, imaging, predictive technologies, screening, detection, diagnostics, and informatics.
The company reported revenue of $2.9 billion in 2025 and employs approximately 11,000 people worldwide.
As a member of the S&P 500, Revvity serves pharmaceutical and biotechnology companies, diagnostic laboratories, academic institutions, and government organizations across more than 160 countries.
